Genomic and transcriptomic analysis of imatinib resistance in gastrointestinal stromal tumors

详细信息    查看全文

• 作者：Tsuyoshi Takahashi ; Asmaa Elzawahry ; Sachiyo Mimaki ; Eisaku Furukawa ; Rie Nakatsuka ; Hiromi Nakamura ; Takahiko Nishigaki ; Satoshi Serada ; Tetsuji Naka ; Seiichi Hirota ; Tatsuhiro Shibata ; Katsuya Tsuchihara ; Toshirou Nishida and Mamoru Kato
• 刊名：Genes, Chromosomes and Cancer
• 出版年：2017
• 出版时间：April 2017
• 年：2017
• 卷：56
• 期：4
• 页码：303-313
• 全文大小：604K
• ISSN：1098-2264

文摘

Gastrointestinal stromal tumors represent the most common mesenchymal tumor of the digestive tract, driven by gain-of-function mutations in KIT. Despite its proven benefits, half of the patients treated with imatinib show disease progression within 2 years due to secondary resistance mutations in KIT. It remains unclear how the genomic and transcriptomic features change during the acquisition of imatinib resistance. Here, we performed exome sequencing and microarray transcription analysis for four imatinib-resistant cell lines and one cell line briefly exposed to imatinib. We also performed exome sequencing of clinical tumor samples. The cell line briefly exposed to imatinib exhibited few single-nucleotide variants and copy-number alterations, but showed marked upregulation of genes related to detoxification and downregulation of genes involved in cell cycle progression. Meanwhile, resistant cell lines harbored numerous genomic changes: amplified genes related to detoxification and deleted genes with cyclin-dependent kinase activity. Some variants in the resistant samples were traced back to the drug-sensitive samples, indicating the presence of ancestral subpopulations. The subpopulations carried variants associated with cell death. Pre-existing cancer cells with genetic alterations promoting apoptosis resistance may serve as a basis whereby cancer cells with critical mutations, such as secondary KIT mutations, can establish full imatinib resistance.